Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant drop in short interest in May. As of May 31st, there was short interest totalling 93,300 shares, a drop of 26.8% from the May 15th total of 127,400 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 322,600 shares, the days-to-cover ratio is currently 0.3 days.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently raised its position in Ernexa Therapeutics stock. Geode Capital Management LLC raised its position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 257,310 shares of the company’s stock after buying an additional 236,875 shares during the quarter. Geode Capital Management LLC owned about 4.76% of Ernexa Therapeutics worth $76,000 as of its most recent SEC filing. Institutional investors and hedge funds own 70.55% of the company’s stock.

Ernexa Therapeutics Trading Up 5.9%

Shares of ERNA opened at $2.53 on Wednesday. Ernexa Therapeutics has a 12-month low of $2.08 and a 12-month high of $39.38. The company has a market capitalization of $10.52 million, a PE ratio of -0.30 and a beta of 5.55. The business’s 50 day moving average is $3.02 and its 200 day moving average is $4.08.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.